# Bayer Targets GLP-1 Side Effect Solutions for India

> Bayer plans to launch products addressing GLP-1 drug side effects in India by 2030.
- Title: Bayer Targets GLP-1 Side Effect Solutions for India | Shortify
- Summary: Bayer plans to launch products addressing GLP-1 drug side effects in India by 2030. Bayer AG will assess digestive health, nutrition, and multivitamin…
- Keywords: bayer, glp-1, side effects, india, consumer health, digestive health, multivitamins, obesity drugs, Targets, Side, Effect, Solutions
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/assessing-products-to-counter-side-effects-of-glp-1-says-bayers-triana/articleshow/134877042.cms
- Author: Rica Bhattacharyya and Vikas Dandekar
- Published: 2026-10-11T20:03:00+00:00
- Read time: 1 min
- Topics: bayer, glp-1, side effects, india, consumer health, digestive health, multivitamins, obesity drugs
## Bayer assesses GLP-1 side effect solutions
Bayer AG is exploring products to address constipation, nausea and muscle loss from GLP-1 obesity drugs in India.

> Bayer AG is assessing opportunities to bring products addressing side effects associated with glucagon-like peptide-1 (GLP-1) obesity drugs to India
## Bayer aims to triple India consumer health business
Bayer plans to triple its consumer health revenue in India by 2030, targeting it as its third-largest global market.

> We should be able to triple the India business in terms of the revenue between now and 2030
## GLP-1 drugs cause significant side effects
GLP-1 obesity drugs cause constipation, nausea and muscle loss requiring counter products in the US market.

> The GLP-1s have brought in a seismic sort of innovation into the market
## Bayer evaluates digestive health products
Bayer identifies digestive health as a key growth area in India with significant gut health challenges.

> We also have a lot of new entrants in our space. We're competing not just with global players but also with local players
## Bayer will launch counter products in India
Bayer will assess and launch digestive health, nutrition and multivitamin products for GLP-1 side effects in India.

> Yes. The team is doing an assessment. We will support the team to bring whatever products they want to bring to India
## Bayer avoids distribution partnerships in India
Bayer plans to build its own distribution network in India rather than partner with local distributors.

> We would run the business ourselves, so we're building our own distribution - and so we would not look for a distributing partner
## Bayer targets affordable product access in India
Bayer aims to make its products accessible to low-income households through pricing and presentation strategies.

> We don't want our products to only be for rich countries that can buy expensive vitamins
## Key takeaway

Bayer AG will assess digestive health, nutrition, and multivitamin products to counter GLP-1 obesity drug side effects in India.